Dexamethasone-Appended Activatable Prodrug Overcoming Multidrug Resistance

Area of Science:

• Oncology
• Drug Development
• Biochemistry

Background:

• Residual tumor cells post-chemotherapy often display multidrug resistance (MDR) and increased invasiveness, leading to metastasis and recurrence.
• Overcoming MDR is crucial for improving cancer treatment efficacy and patient outcomes.

Purpose of the Study:

• To develop and evaluate a novel reactive oxygen species (ROS)-responsive prodrug, Dex-Dox, for overcoming MDR in tumor cells.
• To assess the in vitro and in vivo efficacy of Dex-Dox in drug-resistant cancer models.

Main Methods:

• Conjugation of dexamethasone (Dex) with doxorubicin (Dox) via an oxidative stress-responsive linker to create the Dex-Dox prodrug.
• In vitro assessment of Dex-Dox's effect on drug-resistant cells, including apoptosis induction and anti-angiogenesis activity.
• In vivo therapeutic evaluation and histological analysis in a Dox-resistant tumor mouse model.

Main Results:

• Dex-Dox demonstrated significant enhancement of drug sensitivity, promoted apoptosis, and inhibited angiogenesis in drug-resistant cells in vitro.
• In vivo studies showed that Dex-Dox substantially reduced tumor volumes, particularly in a Dox-resistant mouse model.
• Dexamethasone alone did not exhibit antitumor activity, highlighting the prodrug's specific mechanism.

Conclusions:

• Dex-Dox is a potent ROS-responsive prodrug effective against multidrug-resistant cancer cells.
• The findings underscore Dex-Dox's potential as an innovative therapeutic strategy to combat MDR in cancer treatment.
• Further investigation into Dex-Dox could lead to improved clinical outcomes for patients with resistant tumors.